Skip to main content

About Cure Leukaemia

All funds raised through the Cure Leukaemia Cycling Club will be invested in the national trials Acceleration Programme (TAP).

TAP is a network of specialist research nurses in 15 of the UK’s biggest cities.

This network enables rapid setup and delivery of pioneering blood cancer clinical trials benefitting UK a catchment area of over 20 million people.

Without the nurses and hub funded by Cure Leukaemia, these clinical trials would not run and patients would miss out on potentially life-saving treatment.

Not only do the clinical trials delivered by TAP save lives, they also hasten global progress towards finding effective treatments for all forms of blood cancer.

Beatson West of Scotland Cancer Centre, Glasgow
Belfast City Hospital
St James’s University Hospital, Leeds
The Christie, Manchester
Russell Centre for Clinical Haematology, Nottingham
Centre for Clinical Haematology, Birmingham
University Hospital of Wales, Cardiff
Churchill Hospital, Oxford
Guy’s and St Thomas’, London
University College Hospital (UCL), London
University Hospitals Southampton
Bristol Haematology & Oncology Centre
The Royal Marsden, Surrey
Manchester Royal Infirmary
The Freeman Hospital, Newcastle

‘I thought it was curtains but then along came my miracle. 7 years later and I’m still taking the same dose. It continues to work.

They are remarkable little pills that I take. I got my life back.’

Mark Hill, London

The first patient treated on the ‘MAJIC’ clinical trial

Cure Leukaemia’s funding of the UK Trials Acceleration Programme (TAP) is a game-changer and increases the access for blood cancer patients to potentially transformative new therapies through the delivery of practice informing clinical trials which not only saves lives but also increases investment into this country’s economy. We have seen the urgent importance of clinical trials to combat the COVID-19 virus and we must not lose sight of the transformative role networks like TAP play in connecting blood cancer patients in the UK with critically important clinical trials.

Sir John Bell

Regius Professor of Medicine at the University of Oxford & HM Government Vaccine Taskforce Advisor